Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Breast cancer care in U.S. territories lags behind care in states
Older women residing in the U.S territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers. Their findings were published in the March issue of Health Affairs.
Breast cancer breakthrough may have been found in Connecticut
A big breakthrough in the battle against breast cancer may have been found in Connecticut. The discovery was make by a local researcher and helped by a grant from the Terri Brodeur Breast Cancer Foundation with money raised by the Southern Connecticut Breast Cancer Walk. It starts with hundreds of walkers every fall and ends in a lab. The local fight against breast cancer is spearheaded by the foundation. "I feel like a lot of us clinicians have insight into what's going on with the disease type but it's very hard to compete with people who are doing research full time," said Dr. Erin Hofstatter, Yale Cancer Center. "Terri Brodeur has been valuable in giving me a chance."Source: WFSB
Yale’s advance in breast cancer surgery to be tested in nationwide study
Removing a small amount of extra tissue around a breast cancer tumor may keep a patient from having a recurrence of the cancer or of having to return to the operating table because not all of the malignant cells were removed in the first operation. That’s the theory that’s being tested in a nationwide clinical trial sponsored by the Yale Cancer Center called SHAVE2. Dr. Anees Chagpar, assistant director of global oncology at the Yale School of Medicine and former director of the Breast Center, is the principal investigator. Chagpar oversaw the first SHAVE trial at Yale, which involved 235 patients with stage 0 to stage 3 breast cancer who were given a partial mastectomy, also known as a lumpectomy. Some were given normal lumpectomies, while others had more tissue removed from around the tumor site, known as cavity shave margins.Source: New Haven Register
Breast reconstruction after cancer less common at cash-strapped hospitals
Women with breast cancer who have one or both breasts removed are less likely to get immediate reconstruction surgery at hospitals that are struggling financially, a U.S. study suggests. Even so, the results underscore the importance of women seeing a plastic surgeon to make an informed decision about breast reconstruction, said Dr. Brigid Killelea, co-author of an accompanying editorial and chief of breast surgery at Yale University School of Medicine in New Haven, Connecticut. “I think it is important for patients to understand that getting a referral to a plastic surgeon to discuss reconstruction after mastectomy is standard and in most cases, encouraged; it’s not something extra or unnecessary,” Killelea said by email. Patients shouldn’t feel limited in their treatment options by hospital finances,” Killelea added.Source: Reuters
Five things everyone should know about breast cancer
In 2017, the American Cancer Society estimates more than 250,000 new cases of breast cancer will be diagnosed in the United States, with more than 40,000 deaths. But progress in treatment and early detection has led to improved survival rates, with more than 3 million breast cancer survivors in the U.S. today. With October marking National Breast Cancer Awareness Month, Anees Chagpar, M.D., M.P.H., a breast cancer expert and assistant director for Global Oncology at Yale Cancer Center, sorts out the facts about breast cancer and offers simple ways to reduce risk.
Yale Study: Minority Breast Cancer Patients Less Likely To Have Genetic Test
A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found.Source: Connecticut Health I-Team
Yale researcher gets $792,000 grant from cancer society
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding of a new research grant totaling $792,000 to a researcher at Yale University. The grant is among 109 national research and training grants totaling more than $45 million that will fund investigators at 75 institutions across the United States; 102 are new grants while seven are renewals of previous grants. The grants go into effect July 1. Ryan B. Jensen, Assistant Professor of Therapeutic Radiology at Yale School of Medicine, will begin work on his project titled, “Elucidating Cancer Risk in Homology-Directed Repair Variants.” According to a news release from the cancer society, Jensen’s lab is working to understand how failures in DNA repair contribute to both cancer risk and improved treatment strategies.Source: CT Post
VIDEO: Counseling patients considering contralateral prophylactic mastectomy
The number of women with ipsilateral breast cancer seeking a contralateral mastectomy to reduce their future risk and, essentially, for peace of mind, is increasing. Dr. Anees Chagpar director of the Breast Center, Smilow Cancer Hospital at Yale-New Haven (Conn.), suggests what doctors can include in discussions with these patients.Source: oncologypractice.com
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
New Treatments Keeping Women Alive Longer Through Breast Cancer
Five percent of women diagnosed with breast cancer have metastatic disease, but survival rates are climbing. According to the Breast Cancer Research Foundation, the number of women living with metastatic breast cancer rose to 168,000 last year from 155,000 the year before. New breakthroughs keep women alive longer while researchers race to find the next therapy that will work.Source: WINK
‘This is About Saving Women’s Lives’: Find It Early Act Aims to Increase Breast Cancer Screenings
Congresswoman Rosa DeLauro announced the introduction of the Find It Early Act which, if passed, would require insurance companies to cover mammograms, breast ultrasounds, and MRIs to increase early cancer detection.
Patient Selection for AstraZeneca, Daiichi Breast Cancer Drug Needs Improvement, Experts Say
The rush to use AstraZeneca and Daiichi-Sankyo’s drug Enhertu to treat certain types of breast cancer has far outpaced doctors’ ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.Source: Financial Post
Panel to Examine the Ongoing Evolution of Antibody Drug Conjugates in the Treatment of Breast Cancer
Antibody drug conjugates (ADCs), which use a targeted monoclonal antibody to deliver a cytotoxic payload, are among the most effective breast cancer therapies yet developed. The first Food and Drug Administration approval of an ADC in breast cancer, ado-trastuzumab emtansine, better known as T-DM1, sparked development of numerous new and promising ADCs for breast cancer.Source: SABCS Meeting News
Trastuzumab Deruxtecan Generates OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer
Trastuzumab deruxtecan demonstrated a 34% reduction in the risk of death and a 13-month increase in overall survival compared with treatment of physician’s choice in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who received prior treatment with trastuzumab emtansine.Source: OncLive